

Nxera Pharma to Record Extraordinary Loss on Impairment of Shares of Consolidated Subsidiary (Non-Consolidated)

Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that it has recorded an extraordinary loss as described below. This loss arose from differences in the valuation methods for investments in subsidiaries between Japanese GAAP (“JGAAP”) and International Financial Reporting Standards (“IFRS”). Please note that the extraordinary loss relating to this matter is recorded only in the Company’s non-consolidated financial statements and will be eliminated in the consolidated financial statements; therefore, it will have no impact on the Company’s consolidated results.

(1) Details of the Extraordinary Loss

In accordance with Accounting Standard for Financial Instruments under JGAAP applied for the Company’s non-consolidated financial statements, the Company has determined that there has been a significant decline in the recoverable amount of shares of Nxera Pharma UK Limited, a consolidated subsidiary of the Company, and will record an extraordinary loss of JPY24,335m, as a valuation loss on shares of subsidiaries and associates.

(2) Impact on Financial Results

The above loss on valuation of shares of subsidiaries and associates is recorded only in the Company’s non-consolidated financial statements and will be offset/eliminated in the consolidated financial statements; therefore, it will have no impact on the Company’s consolidated results.

-ENDS-

About Nxera Pharma

Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life

LinkedIn: [@NxeraPharma](#) | X: [@NxeraPharma](#) | YouTube: [@NxeraPharma](#)

QUVIVIQ™ is trademark of Idorsia Ltd.

Enquiries:**Nxera – Media and Investor Relations**

Shinya Tsuzuki, VP, Head of Investor Relations

Maya Bennison, Communications Manager

+81 (0)3 5210 3399 | +44 (0)1223 949390 IR@Nxera.life

MEDiSTRAVA (for International Media)

Mark Swallow, Frazer Hall, Erica Hollingsworth

+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.